Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avation loss narrows; Franchise Brands profit rises

Thu, 03rd Mar 2022 19:32

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Avation PLC - Singapore-based commercial passenger aircraft leasing company - For the six months ended December 31, pretax loss narrows to USD15.9 million from USD60.5 million, due to a much lower impairment loss on aircraft and credit losses. Revenue drops 6% year-on-year to USD57.9 million from USD61.3 million. Avation's aircraft fleet stands at 42, however fleet assets declines 7.0% year-on-year to USD1.00 billion as at December 31 from USD1.08 billion at the end of June.

----------

Franchise Brands PLC - Manchester-based owner of ChipsAway, Willow Pumps and Metro Rod brands - For 2021, pretax profit rises 57% year-on-year to GBP5.8 million from GBP3.7 million the year before, on revenue which grows 17% year-on-year to GBP57.7 million from GBP49.3 million, with double digit sales from Metro Rod and Metro Plumb, as well as a strong recovery from the B2C division. Declares final dividend of 0.9 pence per share, bringing total payout to 1.5p, up 36% from 1.1p. Looking ahead, reports strong start to 2022, with continued sales growth in B2B.

----------

Poolbeg Pharma PLC - London-based pharmaceutical company - For the period from incorporation on March 19 to December 31, posts pretax loss of GBP2.3 million and no revenue as the company continues to develop its severe influenza treatment POLB 001.

----------

Crystal Amber Fund Ltd - Guernsey-based investment company - As at December 31, net asset value per share increases 11% year-on-year to 143.19 pence from 128.99p. For the six month period, delivered NAV negative return of 0.8%, compared to a 4.7% positive return from the Numis Small Cap Index.

----------

JPMorgan Global Growth & Income PLC - invests in companies around the world - As at December 31, net asset value per share increases 6.1% year-on-year to 459.1 pence from 432.3p, while for the six month period, NAV total return is 8.2%, compared to a 7.7% return from the MSCI AC World Index.

----------

t42 IoT Tracking Solutions PLC - Jersey-based provider of tracking, security and monitoring solutions for containers and freight - For 2021, operating loss widens to USD2.7 million from USD1.8 million, on revenue which declines 16% year-on-year to USD4.2 million from USD5.0 million due to supply chain issues and a performance turnaround only taking place near the end of 2021.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - For the six months ended December 31, pretax profit drops 54% to GBP7.3 million from GBP15.8 million a year before, due to a rise in costs and a 10% year-on-year decline in revenue to GBP48.7 million from GBP54.0 million, due to the strategic streamlining of older products. Looking ahead, company has a strong outlook for the full financial year with operating profit on track to meet consensus expectations.

----------

Power Metal Resources PLC - London-based metals exploration company focused in North America, Africa and Australia - For the year ended September 30, pretax loss narrows to GBP623,000 from GBP1.4 million the year before, due to smaller impairment charges, and a slight rise in revenue to GBP37,000 from GBP9,000

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
1 Dec 2020 16:06

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
20 Nov 2020 14:51

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

UK DIRECTOR DEALINGS SUMMARY: Landsec CEO Buys GBP300,000 Worth

Read more
26 Oct 2020 14:17

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

Read more
26 Oct 2020 13:37

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

Read more
23 Sep 2020 14:02

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

Read more
4 Sep 2020 19:39

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Read more
3 Sep 2020 15:31

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
15 Jul 2020 09:03

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.

Read more
9 Jul 2020 21:19

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Read more
9 Jul 2020 16:26

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.

Read more
24 Jun 2020 11:53

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Read more
24 Jun 2020 10:12

Allergy Therapeutics on track to 'significantly' exceed FY expectations

(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.

Read more
4 Mar 2020 10:46

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Read more
26 Feb 2020 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.